T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.
T-cells are known to play a crucial role in the human immune system.
An innovative test that determines the quality and quantity of inactive HIV viruses in the genes of HIV patients may ultimately give scientists a better idea of effective drugs.
Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.
Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread.
Researchers from Duke-NUS Medical School, the National Centre for Infectious Diseases (NCID), and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs have discovered that antibodies against SARS-CoV-2 decline at different speeds, and these antibodies last for only a few days in some people but remain for many years in other individuals.
Scientists from the University of Basel have gained insights into the specialization of T cells.
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.
Immunologists have plotted a previously unfamiliar biological pathway through which the immune system produces T cells that destroy viruses.
For the first time, scientists have discovered the genetic predisposition of severe COVID-19 disease.
Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.
Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique (INRS) has identified a therapeutic approach to restore the effectiveness of immune cells.
There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called "checkpoint proteins."
CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.
A new study performed by scientists from Ludwig-Maximilians-Universitaet Muenchen (LMU) has demonstrated that putatively immature dendritic cells in young children can trigger powerful immune responses. The findings may result in better vaccination protocols.
Highly complicated processes constantly take place in our body to keep pathogens in check: The T-cells of our immune system are busy searching for antigens - suspicious molecules that fit exactly into certain receptors of the T-cells like a key into a lock. This activates the T-cell and the defense mechanisms of the immune system are set in motion.
A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.